# Interferon types I, II and III

Source: https://onco.cc/terms/interferons/  
OnCo record `interferons` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Interferons are signalling proteins that change how cells respond to infection, stress and immune activity. There are three families with different receptors, and a short exposure, a long exposure and a missing response can each mean something different for a tumour.

## Summary

Type I interferons (alpha and beta) share a receptor system found on many cell types. Type II (gamma) uses a different receptor system and is made mainly by activated immune cells. The type I receptor, IFNAR, is expressed on virtually all nucleated cells and the type III receptor mainly on epithelial cells (Lazear et al., 2019), and interferon gamma production is largely restricted to immune cells although its receptor is widely expressed (Schneider et al., 2014). Interferon gamma effects include upregulated antigen processing and presentation and an antiviral state (Schroder et al., 2004). Type III (lambda) signals through a distinct receptor complex, made of IFN-lambda receptor 1 and IL-10 receptor 2, that signals through the Jak-STAT pathway (Kotenko et al., 2003); in mice the response to lambda was prominent in stomach, intestine and lung, very low in the brain and spleen, and restricted to epithelial cells in kidney and brain (Sommereyns et al., 2008). Types I, II and III group interferons by receptor usage; the alpha, beta, gamma and lambda names do not measure dose or potency. Many responses run through JAK and STAT proteins and can increase antigen-processing and HLA machinery, antiviral defences, or regulatory signals; producing an interferon, receiving it and carrying out a function are separate steps.

## Fields

- Kind: Term
- Last checked: 2026-11-10
- Also known as: interferon; interferons

## Notes

- In cancer, timing and the receiving cell decide the meaning. In mice, endogenous type I interferon was required to prevent the growth of carcinogen-induced and transplanted tumours, and the critical targets were host blood-lineage cells, not the tumour cells, which differs from interferon gamma, where tumour cells are important targets (Dunn et al., 2005). Prolonged interferon signalling in experimental tumours, driven by type II and maintained by types I and II, produced a resistance programme to checkpoint blockade that was PD-L1-dependent and independent, and biomarkers of that programme associated with progression after anti-PD-1 therapy in the patient data analysed (Benci et al., 2016). In four people with metastatic melanoma whose tumours first responded to pembrolizumab and later relapsed, paired biopsies showed loss-of-function mutations in JAK1 or JAK2 in two (with no response to interferon gamma in the mutant cells) and a truncating mutation in B2M, which removes class I display, in a third (Zaretsky et al., 2016). Four patients do not give a frequency for any cancer.
- Reading an interferon result needs the family, the receiver, the timing and the readout. An interferon signature in RNA is not an interferon concentration and cannot identify the producing cell. Capacity to respond under a controlled exposure is not evidence of natural exposure, and an inducible display gene score is not a count of displayed peptide complexes or a measure of tumour killing. A working display pathway can also not repair a structural loss of an HLA allele or a processing component, and stronger or longer signalling is not safer or more beneficial by default. A report on an interferon experiment should name the family, the preparation, the concentration or units, the exposure time, the cell identity and viability, and the controls, and should keep three quantities apart: a concentration in picograms per millilitre, RNA expression, and a change from a matched unstimulated condition (OnCo reporting advice). A fourfold rise in a display-gene score is not fourfold killing.
- Three measurement questions need separate answers. Protein concentration in a named fluid, for example picograms per millilitre, measures amount per volume. An RNA expression or signalling-protein readout measures a sampled cellular response. Change after controlled exposure relative to a matched unstimulated condition tests response capacity in that experiment. The last result does not establish that the same exposure occurred naturally, and a fluid concentration does not identify every producer or tissue exposure. Rodero et al. (2017) measured interferon-alpha protein, interferon-stimulated gene expression and antiviral activity separately; their activity assay measured protection from viral cytopathic effects, not tumour killing.
- Ayers et al. (2017) studied an interferon-gamma-related tumour RNA profile associated with response to pembrolizumab. That expression score is not an interferon protein concentration or a count of killed cells, and an association among treated patients alone does not establish treatment benefit relative to no treatment. For a controlled-exposure result, report interferon family, preparation, concentration, exposure time, cell identity, viability and controls. A low baseline score can coexist with an inducible response; intact gene sequence alone does not establish working signalling. As a measurement inference, changing an expression score from 1 to 4 relative units is a fourfold change in that readout, not evidence of fourfold killing, peptide display or matching receptor recognition.

## Sources

- IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.: https://doi.org/10.1038/ni875
- IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo.: https://doi.org/10.1371/journal.ppat.1000017
- A critical function for type I interferons in cancer immunoediting.: https://doi.org/10.1038/ni1213
- Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.: https://doi.org/10.1016/j.cell.2016.11.022
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.: https://doi.org/10.1056/nejmoa1604958
- Shared and Distinct Functions of Type I and Type III Interferons.: https://doi.org/10.1016/j.immuni.2019.03.025
- Interferon-stimulated genes: a complex web of host defenses.: https://doi.org/10.1146/annurev-immunol-032713-120231
- Interferon-gamma: an overview of signals, mechanisms and functions.: https://doi.org/10.1189/jlb.0603252
- Rodero et al., 2017: Interferon-alpha protein and cellular sources: https://doi.org/10.1084/jem.20161451
- Ayers et al., 2017: Interferon-gamma-related mRNA profile: https://doi.org/10.1172/JCI91190

## Connected records

- targets: [B2M](https://onco.cc/targets/b2m/), [IFNGR1](https://onco.cc/targets/ifngr1/), [Interferon alpha receptor (IFNAR1)](https://onco.cc/targets/ifnar1/), [JAK1](https://onco.cc/targets/jak1/), [JAK2](https://onco.cc/targets/jak2/)
- terms: [Cytokine](https://onco.cc/terms/cytokine/), [Immune system](https://onco.cc/terms/immune-system/), [Interferon-gamma gene signature (T-cell-inflamed signature)](https://onco.cc/terms/interferon-gamma-signature/)
- technologies: [Cytokines & engineered cytokines](https://onco.cc/technologies/cytokine-therapy/)

---
JSON: https://onco.cc/api/v1/entities/interferons.json